Trial Profile

Randomized, Open-label, Parallel, Active-controlled, Multicenter Study of Efficacy and Safety of Fixed-dose Combination of Fluticasone /Formoterol /Glycopyrronium for the Treatment of Patients with Chronic Obstructive Pulmonary Disease

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluticasone Formoterol Glycopyrronium Eurofarma (Primary) ; Beclometasone/formoterol/glycopyrrolate
Indications Chronic obstructive pulmonary disease
Focus Therapeutic Use
Acronyms TRIPLAR
Sponsors Eurofarma

14 Feb 2025 Planned End Date changed from 30 Jul 2028 to 1 Aug 2028.
14 Feb 2025 Planned primary completion date changed from 30 Nov 2027 to 1 Aug 2028.
14 Feb 2025 Planned initiation date changed from 28 Feb 2026 to 1 Sep 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com